| |
Received treatment (N = 18)
|
Untreated (N = 11)
|
|---|
|
Media age (IQR)—years
|
47.5 (45–55.7)
|
39 (35–53)
|
|
Female sex—n (%)
|
13 (72.2%)
|
5 (45.4%)
|
|
Covid-19 pneumonia—n (%)
|
11 (61.1%)
|
4 (36.3%)
|
|
Covid-19 severity—n (%)
| | |
|
Mild
|
5 (27.7%)
|
2 (18.1%)
|
|
Moderate
|
4 (22.2%)
|
2 (18.1%)
|
|
Severe
|
9 (50%)
|
7 (63.6%)
|
|
COVID-19 acute antiviral treatment—n (%)
|
13 (72.2%)
|
6 (54.5%)
|
|
Positive results of plasma PCR—n (%)
|
9 (50%)
|
4 (36%)
|
|
At least one positive PCR—n (%)
|
10 (55.5%)
|
5 (45.4%)
|
|
Basal functional status
| | |
|
Grade 0—n (%)
|
0 (0%)
|
0 (0%)
|
|
Grade I—n (%)
|
1 (5.5%)
|
6 (54.54%)
|
|
Grade II—n (%)
|
5 (27.7%)
|
3 (27.27%)
|
|
Grade III—n (%)
|
4 (22.2%)
|
1 (9%)
|
|
Grade IV—n (%)
|
8 (44.4%)
|
1 (9%)
|
